
Novo Nordisk (NVO) Stock Forecast & Price Target
Novo Nordisk (NVO) Analyst Ratings
Bulls say
Novo Nordisk leads the global branded diabetes treatment market with approximately 20% market share, significantly benefiting from the expected 20% growth in North America, which is projected to boost revenue estimates to DKK 24.9 billion. The continued dominance of Wegovy and Ozempic, bolstered by their strong cultural and physician recognition, positions the company for robust sales growth moving forward. Additionally, the favorable outcomes from clinical trials, such as the SURMOUNT-5 trial, which demonstrated the superior efficacy of tirzepatide over semaglutide, further enhances Novo Nordisk's competitive edge in the diabetes and obesity treatment sectors.
Bears say
Novo Nordisk's stock faces a negative outlook primarily due to anticipated lower than expected revenue growth from its incretin products, Ozempic and Wegovy, which is projected to decline by 10%. Current revenue estimates for North America indicate a significant shortfall, with projections of DKK 12.8 billion for Wegovy in Q1 2025, notably below the consensus expectation of DKK 14.4 billion. This trend suggests potential challenges in meeting market expectations and could negatively impact future financial performance and investor sentiment.
This aggregate rating is based on analysts' research of Novo Nordisk and is not a guaranteed prediction by Public.com or investment advice.
Novo Nordisk (NVO) Analyst Forecast & Price Prediction
Start investing in Novo Nordisk (NVO)
Order type
Buy in
Order amount
Est. shares
0 shares